TherapeuticsMD, Inc. (TXMD) Balance Sheet

NASDAQ: TXMDAssets, liabilities, debt and equity over 10 years.

TXMD balance sheet, 2025

December 31, 2025 · U.S. dollars

$37.7M assets = $10.8M liabilities + $26.9M equity

What it owns$37.7MCash & ST investments: $7.5M (19.9%)Cash & ST investments$7.5M · 20%Receivables: $3.5M (9.4%)Receivables $3.5MOther current: $3.4M (9.1%)Other current $3.4MPP&E: $5.3M (14.1%)PP&E$5.3M · 14%Goodwill & intangibles: $3.8M (10.0%)$3.8MOther non-current: $14.2M (37.6%)Other non-current$14.2M · 38%=How it is financed$37.7MCurrent liabilities: $4.8M (12.7%)Current liabilities$4.8M · 13%Other LT liabilities: $6.0M (15.9%)Other LT liabilities$6.0M · 16%Shareholders’ equity: $26.9M (71.4%)Shareholders’ equity$26.9M · 71%

Both columns are drawn to the same scale: what TXMD owns equals what it owes plus shareholders’ equity. Hover a block for its value.

TXMD financial health

Current ratio3.02
Comfortable · current assets cover current liabilities 3.02×
Debt / equity0.23
Low leverage · $0.23 of debt for each $1 of equity
Equity / assets71.4%
Equity-funded · of assets funded by shareholders
Cash / debt122.7%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles10.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

TXMD balance sheet trends, 2016–2025

TherapeuticsMD, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$142.5M2016$37.7M2025−13.7%/yr
Total liabilities$15.0M2016$10.8M2025−3.6%/yr
Shareholders’ equity$127.5M2016$26.9M2025−15.9%/yr
Cash & short-term investments$131.5M2016$7.5M2025−27.3%/yr
Total debt$73.4M2018$6.1M2025−29.9%/yr
Net cash (debt)$88.2M2018$1.4M2025−$86.8M
Working capital$124.4M2016$9.7M2025−$114.8M
Book value per share$32.512016$2.322025−25.4%/yr
Current ratio9.3020163.022025−6.29
Debt / equity0.7520180.232025−0.53
Shares outstanding3.9M201611.6M2025+12.8%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

TXMD assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

TXMD liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

TXMD debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

TXMD balance sheet

TherapeuticsMD, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$7.5M$5.1M$4.3M$38.1M$64.9M$80.5M$160.8M$161.6M$127.1M$131.5M
Cash & equivalents$7.5M$5.1M$4.3M$38.1M$64.9M$80.5M$160.8M$161.6M$127.1M$131.5M
Short-term investments————————$0$0
Receivables$3.5M$3.6M$3.1M$0$36.2M$32.4M$24.4M$11.1M$4.3M$4.5M
Inventory$0$0$0$0$7.6M$8.0M$11.9M$3.3M$1.5M$1.1M
Other current assets$3.4M$1.3M$4.4M$17.3M$10.8M$7.5M$11.3M$10.8M$6.6M$2.3M
Total current assets$14.4M$9.9M$11.8M$55.4M$119.5M$128.4M$208.4M$186.8M$139.6M$139.4M
Property, plant & equipment (net)$5.3M$6.1M$6.9M$7.7M$9.1M$11.5M$12.6M$472,683$437,055$516,839
Goodwill & intangible assets$3.8M$4.3M$6.1M$6.9M$7.1M$41.4M$44.5M$24.1M$3.1M$2.4M
Long-term investments$0$0$0$0$0$0$0$0$0$0
Other non-current assets$14.2M$18.5M$18.5M$20.5M$33.8M$253,000$473,009$639,301$139,036$139,036
Total assets$37.7M$38.8M$43.3M$90.5M$169.5M$181.6M$266.0M$212.0M$143.2M$142.5M
Liabilities
Accounts payable$377,000$258,000$27,000$2.2M$3.4M$21.1M$19.2M$22.7M$4.1M$7.4M
Short-term debt$975,000$1.6M$1.5M$1.4M$189.6M$2.3M$1.5M———
Deferred revenue———$1.0M$39.6M−$2.3M−$1.5M———
Total current liabilities$4.8M$5.2M$6.9M$46.8M$252.9M$59.2M$53.0M$41.1M$13.3M$15.0M
Long-term debt$0$0$0$0$0$237.7M$194.6M$73.4M$0$0
Lease obligations$6.1M$7.2M$8.0M$8.8M$8.1M$10.9M$10.6M———
Other long-term liabilities$6.0M$6.3M$7.2M$8.5M$10.2M$8.7M$9.1M$0$0$0
Total liabilities$10.8M$11.5M$14.0M$55.3M$263.1M$305.6M$256.8M$114.5M$13.3M$15.0M
Shareholders' equity
Common stock & paid-in capital$11,000$11,000$11,000$9,000$9,000$300,000$271,177$240,463$216,430$196,688
Retained earnings (deficit)−$952.4M−$951.8M−$949.6M−$939.4M−$1.05B−$878.9M−$695.4M−$519.3M−$386.7M−$309.7M
Treasury stock————————$0$0
Accumulated other comprehensive income——$0$0$0—−$968,824−$553,630−$372,218−$230,617
Minority interest————————$0$0
Total shareholders' equity$26.9M$27.4M$29.3M$35.1M−$93.6M−$124.0M$9.2M$97.5M$129.9M$127.5M
Key figures
Total debt$6.1M$7.2M$8.0M$8.8M$197.7M$248.6M$205.3M$73.4M——
Net cash (debt)$1.4M−$2.1M−$3.7M$29.3M−$132.8M−$168.1M−$44.5M$88.2M——
Working capital$9.7M$4.8M$4.9M$8.5M−$133.4M$69.2M$155.4M$145.7M$126.2M$124.4M
Tangible book value$23.1M$23.0M$23.2M$28.2M−$100.8M−$165.4M−$35.3M$73.4M$126.8M$125.1M
Book value per share$2.32$2.37$2.80$3.89−$11.76−$22.49$1.87$21.67$31.60$32.51
Shares outstanding11.6M11.5M10.4M9.0M8.0M5.5M4.9M4.5M4.1M3.9M
Current ratio3.021.921.721.180.472.173.934.5510.489.30
Quick ratio2.301.671.080.810.401.913.494.209.879.08
Debt / equity0.230.260.270.25——22.310.75——
Equity / assets71.4%70.5%67.6%38.9%−55.2%−68.3%3.5%46.0%90.7%89.5%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 30, 2026); data from EODHD.

TXMD financial position

At the end of fiscal 2025 (December 31, 2025), TherapeuticsMD had total assets of $37.7 million (down 3.0% from a year earlier), total liabilities of $10.8 million and shareholders' equity of $26.9 million. It held $7.5 million in cash and short-term investments against $6.1 million of debt, a net cash position of $1.4 million. Its current ratio was 3.02. In the latest quarter (ended June 30, 2026) total assets were $37.5 million and equity $27.1 million.

Related: TXMD income statement, TXMD cash flow statement, TXMD key metrics. See the TXMD stock overview for the latest quote and news.

TXMD balance sheet FAQ

What are TherapeuticsMD's total assets?

TherapeuticsMD reported total assets of $37.7 million at the end of fiscal 2025 (December 31, 2025), compared with $38.8 million a year earlier.

How much debt does TherapeuticsMD have?

TherapeuticsMD had $6.1 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.23.

How much cash does TherapeuticsMD have?

TherapeuticsMD held $7.5 million in cash and short-term investments at the end of fiscal 2025; with $6.1 million of debt that is net cash of $1.4 million.

What is TherapeuticsMD's book value?

TherapeuticsMD's shareholders' equity (book value) was $26.9 million at the end of fiscal 2025, or $2.32 per share.

What is TherapeuticsMD's current ratio?

TherapeuticsMD had current assets of $14.4 million and current liabilities of $4.8 million, a current ratio of 3.02 (it can cover its short-term obligations).

How much goodwill does TherapeuticsMD have?

TherapeuticsMD carried $3.8 million of goodwill and intangible assets, 10.0% of total assets, at the end of fiscal 2025.

Drug Manufacturers - Specialty & Generic: balance sheet